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Purpose: Epilepsy is more common in people with intellectual disabilities than in the general population.
However, reported prevalence rates vary widely between studies. This systematic review aimed to
provide a summary of prevalence studies and estimates of prevalence based on meta-analyses.
Method: Studies were identiﬁed via electronic searches using Medline, Cinahl and PsycINFO and cross-
citations. Information extracted from studies was tabulated. Prevalence rate estimates were pooled
using random effects meta-analyses and subgroup analyses were conducted.
Results: A total of 48 studies were included in the tabulation and 46 studies were included in meta-
analyses. In general samples of people with intellectual disabilities, the pooled estimate from 38 studies
was 22.2% (95% CI 19.6–25.1). Prevalence increased with increasing level of intellectual disability. For
samples of people with Down syndrome, the pooled estimate from data in 13 studies was 12.4% (95% CI
9.1–16.7), decreasing to 10.3% (95% CI 8.4–12.6) following removal of two studies focusing on older
people. Prevalence increased with age in people with Down syndrome and was particularly prevalent in
those with Alzheimer’s/dementia.
Conclusion: Epilepsy is highly prevalent in people with intellectual disabilities. Services must be
equipped with the skills and information needed to manage this condition.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Intellectual disability (often referred to as ‘learning disabil-
ities’ in the United Kingdom) refers to a signiﬁcant general
impairment in intellectual functioning that is acquired during
childhood, typically operationalised as scoring more than two
standard deviations below the population mean on a test of
general intelligence [1]. While estimates of the prevalence of
intellectual disability vary widely, it has been estimated that
approximately 2% of the adult population have intellectual
disability [2,3].
In the general population, estimates of the prevalence of
epilepsy are in region of 0.6% [4,5] to 1% [6,7]. In people with
intellectual disabilities, estimates of the prevalence of epilepsy
vary due to differences in the methods used and inherent
population biases [8]. Reported rates range, for example, from
16.1% of 1595 people with intellectual disabilities identiﬁed in
South Wales [9] to 30.7% in a random sample of 753 people with* Corresponding author. Tel.: +44 1524 592895; fax: +44 1524 592658.
E-mail address: j.m.robertson@lancaster.ac.uk (J. Robertson).
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reintellectual disabilities aged 40 or more from Ireland’s National
Intellectual Disability Database (NIDD) [10]. In a systematic review
of the prevalence of chronic health conditions in children with
intellectual disabilities, the most common condition was epilepsy
[11] with prevalence rates in the 14 studies identiﬁed ranging from
5.5% to 35.0%, with an overall weighted mean prevalence rate of
22.0% (95% CI 20.8–23.2).
Despite variation in reported prevalence ﬁgures, it is clear that
the prevalence of epilepsy in people with intellectual disabilities is
much greater than in the general population. Further, for people
with intellectual disabilities and epilepsy, co-morbidities may be
common. Over half of a representative sample of children with
intellectual disability and active epilepsy were reported to have a
psychiatric diagnosis [12]. However, conﬂicting ﬁndings exist and
there is no consensus as to whether people with both intellectual
disability and epilepsy are at increased risk of psychiatric
morbidity compared to their peers with either epilepsy or
intellectual disability alone [13].
The prevalence of epilepsy also increases with increasing
severity of intellectual disabilities. In the Oeseburg et al. [11]
review, the lower rate of 5.5% was for children with borderline to
moderate intellectual disability [14], whilst the rate of 35.0% wasserved.
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wide differences highlight the need to examine prevalence rates
taking into account factors such as the degree of intellectual
disability of the sample. Samples based on, for example, those in
contact with intellectual disability services are likely to miss out
some people with less severe intellectual disabilities. A further
issue is that the ascertainment of epilepsy is not consistent across
studies, both in terms of the deﬁnition of epilepsy used, and how
the information is collected.
The aim of this review is to summarise existing research on the
prevalence of epilepsy in people with intellectual disabilities,
including studies relating speciﬁcally to people with Down
syndrome which is the most common genetic cause of intellectual
disabilities [16]. The review also aims to provide pooled prevalence
estimates for studies taking into account factors such as age and
level of intellectual disability. Whilst existing reviews have
considered the prevalence of epilepsy in people with intellectual
disabilities, these reviews do not cover more recent studies on
prevalence that now provide more data, particularly in relation to
adults with intellectual disabilities. As highlighted in one earlier
review, adults have previously been underrepresented in research
on the epidemiology of epilepsy in people with intellectual
disabilities, with the vast majority of published data pertaining to
children [8]. As this review aims to estimate epilepsy prevalence in
the general population of people with intellectual disabilities or
Down syndrome, it does not include studies relating to less
common speciﬁc genetic conditions associated with intellectual
disabilities, although it is evident that work on such conditions has
been published [17].
2. Method
Electronic literature database searches were conducted in
Medline, Cinahl and PsycINFO on EBSCO. In addition, the reference
lists of articles meeting the inclusion criteria were searched. The
reference lists of key book chapters were also searched [18–
20]. Searches were completed on 19 June 2014. Searches included
terms relating to both prevalence and mortality to create a pool of
articles on prevalence or mortality, with articles on mortality being
retained for a separate review. Searches combined terms for
epilepsy, intellectual disabilities, and prevalence/mortality with
the Boolean operator ‘and’. Full details of the search terms are
given in Appendix A.
2.1. Inclusion criteria
 Peer reviewed
 English Language full text
 Published from 1990
 Primary research
 Present exact ﬁgures on the prevalence of epilepsy
 Samples where 50% or more have intellectual disabilities or
mixed samples where results are disaggregated for people with
intellectual disabilities
 Studies using representative samples of people with intellectual
disabilities or samples representative of speciﬁc sub-groups of
people with intellectual disabilities (e.g. speciﬁc level of
intellectual disability, speciﬁc age band)
2.2. Exclusion criteria
 Case studies
 Case series
 Reviews
 Studies based on neonates (new born infants up to 28 days after
birth) Studies on conditions where intellectual disabilities cannot be
assumed (e.g. cerebral palsy) where results not disaggregated for
people with intellectual disabilities
 Studies on speciﬁc syndromes associated with intellectual
disabilities with the exception of Down syndrome
 Studies where ascertainment of epilepsy could be confounded
with febrile seizures
 Studies employing samples unrepresentative of speciﬁc sub-
groups of people with intellectual disability e.g. only those
attending for inpatient specialist medical care
 Studies not presenting exact ﬁgures
Initially, titles and abstracts were used to exclude those
studies which were obviously not within the scope of reviews on
prevalence or mortality. Those retained for further screening
were those for which relevance could not be assessed without
accessing full text, or those that were chosen as potentially
within scope. These studies were screened by the ﬁrst and
second author and discussed until consensus was reached on
whether or not they met the inclusion criteria. Those relevant to
other future planned reviews (e.g. mortality) were ﬁled for
future reference.
Where multiple articles used the same sample or samples were
likely to have considerable overlap, only the most recent study was
included. One exception was a study based on adults with
intellectual disabilities registered with the Leicestershire Intellec-
tual Disability Register for the period 1993–2010 which reported a
prevalence of 19.1% in a sample of 5391 [21]. As this study focuses
on sudden and unexpected death in epilepsy (SUDEP), it does not
outline the methodology for obtaining this estimate. As such, it
was decided to include an earlier study based on the same register
which focused on epilepsy prevalence [22]. A further study
including only people with Down syndrome which was partly
based on the Leicestershire Intellectual Disability Register was also
included [23].
Information from the included studies was extracted by the ﬁrst
author and this information was tabulated (see Table 1).
2.3. Quality assessment
A gold standard to evaluate the quality of observational
research does not exist [24]. A method for evaluating aspects of
quality considered important in relation to obtaining valid
estimates of the prevalence of epilepsy was developed. The
selected quality indicators were:
1. Deﬁnition of epilepsy:
 Score 2: Deﬁnition given (e.g. ILAE)
 Score 1: Partial deﬁnition given – some information (e.g.
database codes used, epilepsy diagnosis) but incomplete
 Score 0: Not stated (no criteria for epilepsy given)
2. Ascertainment of epilepsy – this refers to the identiﬁcation of
those in the sample with epilepsy and not any subsequent
follow up of those identiﬁed as having possible epilepsy. The
following scores were allocated:
 Score 1: Questionnaire self-completion by informant
 Score 2: Interview with informant
 Score 3: Extracted from records or databases
 Score 4: Clinical examination
If multiple methods were used, the highest level was entered
as the score.
3. Prevalence ﬁgures presented for subgroup(s). A score of 1 was
allocated for each of the following subgroups for which
prevalence ﬁgures were reported.
Table 1
Summary of included studies giving prevalence rates for epilepsy in people with intellectual disabilities. Figures undermale, and levels of ID columns relate to characteristics of the study sample. Sorted by author name. Studies only
looking at Down syndrome listed separately at end of table.
Authors, year and
quality scoreb
Country of study Key sample features Sample source Age range (mean
(SD); median)
Male % Borderline ID % Mild
ID %
Moderate
ID %
Severe
ID %
Profound
ID %
Unspeciﬁed
ID %
Airaksinen et al.
(2000) [42]
10 (2/4/4)
Finland (Kuopio
Province)
Children with ID born
1969–1972 in one
province followed until
age 22. CP 11%. LS ns.
School achievement tests
and social services
register
Prevalence at age
22 yrs given
55a – 49a 51a  c  –
Arvio and Sillanpa¨a¨
(2003)
[43]
4 (0/3/1)
Finland People with SPID. DS
14.3%, AE 19.3%, FXS 3.9%.
LS ns
Register of District Centre
for ID (all in catchment)
1–72 (ns; ns) ns – – – 52.5 47.5 –
Benassi et al.
(1990) [52]
3 (0/3/0)
Italy Children with ‘severe’ ID
(IQ50). DS 22.2%. LS ns.
System recording all
school age children with
ID
3–13 (ns; ns) 63.3 – – 100   –
Christianson
et al. (2002)
[56]
3 (0/2/1)
South Africa Children with ID in rural
households, up to IQ
80. DS 2.1%, CP 8.4%
Rural villages 2–9 (ns; ns) 61.3a ! 81.9a 18.1a   –
David et al.
(2014) [53]
4 (0/3/1)
France (Ise`re) Children with mild ID
born 1997 living in one
county in 2008. LS ns
Maisons De´partementales
des Personnes
Handicape´es (MDPH) and
Dept of Education
9–13a (ns; ns) ns – 100 – – – –
Dekker and Koot
(2003) [14]
2 (0/2/0)
Netherlands Children with borderline
to moderate ID living in
family home. DS 5.3%
Schools for ID 7–20 (12.9 (3.0);
ns)
61.8 100   – – –
Fernell (1998)
[38]
3 (0/3/0)
Sweden Children with ‘severe’ ID
(IQ<50–55). CP 23.4%, DS
20.3%. LS ns
Register of Board for
Provision of Services to
the Mentally Retarded
BPSMR): all in one
municipality
3–16 (ns; ns) 62.5 – – 100   –
Forsgren et al.
(1990) [39]
8 (2/2/4)
Sweden All adults and children
with ID in one County on a
prevalence day. DS 13.7%,
Fragile X 2.3%, RS 0.3%. LS
any
Register of BPSMR,
neurology and paediatric
departments
All (ns) ns ns ns ns ns ns 100
Gittins and Rose
(2008) [32]
5 (1/3/1)
England, West
Midlands
Adults with PMLD in one
health district. LS family
home, residential care,
family placement
Special needs register of
LD service, CLDTs
18–51+ (37 (ns);
ns)
ns – – – – 100 –
Goulden et al.
(1991) [49]
9 (2/3/4)
Scotland, Aberdeen Children with ID born
1951–1955 followed to
age 22. CP 14.9%, DS 5.1%.
LS ns
Receiving special services
for ID prior to leaving
school
Prevalence ﬁgure
given is for age 22
ns – 78.6a 21.4a   –
Hand and Reid
(1996) [60]
1 (0/1/0)
New Zealand (NZ) All NZ older adults with ID
born before 1940, CP 4%,
DS 13%. LS any
Multiple agencies and
local networking
51–88 (ns; ns) 50.0 4.0 34.5 38.3 15.4 5.1 2.7
Haveman et al.
(2011) [55]
4 (1/2/1)
14 European
countries (1 of
which upper
middle income)
Adults with ID living in
Europe. LS any
Mainly service provider
registers
19–90 (41 (ns); ns) 50.6 – 22.7 28.2 20.7 11.8 16.6
Hove and Havik
(2010) [47]
1 (0/1/0)
Norway Adults with ID living in
community. DS 16.4%, CP
9.1%. LS includes
psychiatric wards if part
of community care
programme
Social services 18–97 (41.8 (14.5);
ns)
53.1 – 21.6 41.0 18.0 13.0 6.4
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Jelliffe-Pawlowski
et al. (2003) [25]
5 (1/3/1)
US Children with ID from a
larger cohort born with or
without birth defects. CP
46.8%. LS ns
ID those receiving services
from California
Department of
Developmental Services
7–9 (ns; ns) ns – 52.7 47.3   –
Koskentausta et al.
(2002) [15]
4 (0/3/1)
Finland All children with ID born
1982 to 1988 in one
district. LS mostly
parental home
Patient register of
Rehabilitation Centre,
hospitals, special schools
6–13 (9.7 (ns); ns) 59.4 – 56.1 19.4 11.6 12.9 –
Lakhan (2013)
[61]
7 (0/4/3)
India Children with ID living in
village households in one
of poorest districts. DS
7.3%, CP 31.3%
Door to door survey in
63 villages
3–18 (ns; ns) 52.7 1.9 30.2 38.2 24.0 5.7 –
Lewis et al. (2000)
[58]
(2000)
3 (1/2/0)
Australia Young people with ID, LS
any
Services in ﬁve districts of
New South Wales
8–22 (ns; ns) 52.0 ! 29.8a 40.8a 24.2a 5.1a –
Lin et al. (2003)
[62]
1 (0/1/0)
Taiwan People with ID registered
with day-care
institutions, 92.6% age
<26. LS ns
Community-based day-
care institutions
1–26+ (13.7 (ns);
ns)
61.2 – 4.9 17.4 40.9 24.9 –
Matthews et al.
(2008) [46]
3 (1/2/0)
Wales Adults with ID registered
with GP. LS independent
10%, family home 46%,
staffed home 44%
40 general practices 17–86 (41 (ns); ns) 44 ns ns ns ns ns 100
McBrien and Macken
(2009) [35]
3 (0/3/0)
Ireland Children with moderate,
to profound ID. Any
chromosonal or genetic
cause 48.5%, DS 24.7%. LS
ns
Centre providing
educational and health
services for all individuals
withmoderate, severe and
profound ID in one area
5–19 (ns; 12) 66.0 – – 64.9 35.1  –
McCarron et al.
(2014) [10]
6 (1/2/3)
Ireland Older adults with ID, 3.1%
with DS and dementia. LS
all
National database (all ID
eligible to receive
services)
40–65+ (54.8 (9.6);
ns)
45 – 24 46 24 5 –
McDermott et al.
(2005) [26]
6 (2/3/1)
US Adults with ID receiving
primary health care. CP
24.9%, DS 8.9%. LS ns
Large urban or small rural
primary care practice
20–60+ aged mean
36.5 (13.9); ns)
52.0a – 35.9 22.9 41.2  –
McGrother et al.
(2006) [22]
6 (1/2/3)
England, Leicester-
shire
Adults with ID known to
services. LS any
Leicestershire LD Register 20–70+ (ns; ns) 56.6 ns ns ns ns ns 100
Memisevic and
Sinanovic (2009)
[51]
7 (1/3/3)
Bosnia and Herze-
govina, Sarajevo
Childrenwithmoderate or
mild ID. Organic brain
injury 21.0%, DS 20.4%,
other genetic syndromes
13.2%. LS ns
Two special schools 7–15 (ns; ns) 62.9a – 50.9 49.1 – – –
Molteno et al. (2001)
[57]
1 (0/1/0)
South Africa, Cape
Town
Children with ID at special
schools. CP 33.8%. LS ns
Two special schools and a
training centre
6–18 (ns; ns) 55.5 – 35.8 38.6 13.8 10.7 1.1
Morgan et al. (2003)
[9]
7 (1/3/3)
Wales People with ID mainly age
16+ in contact with health
or social services. LS any
Social services register,
inpatient and outpatient
databases, MH hospital
dataset
15–85+ (ns; ns) ns ns ns ns ns ns 100
Murphy et al. (1995)
[27]
4 (0/3/1)
US Children with ID born
1975 to 1977 living in
study area at age 10. CP
12.3%. LS ns
Schools, hospitals, other
health and social services
10 year olds 59.2 – 69.9 30.1   –
Nordin and Gillberg
(1996) [40]
6 (2/4/0)
Sweden All children with ID born
1974 to 1988 in one
region. CP 8.9%, DS 8.9%.
LS ns
Habilitation and
educational services
3–18 (ns; ns) 63.4a – 56.4 43.6   –
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Table 1 (Continued )
Authors, year and
quality scoreb
Country of study Key sample features Sample source Age range (mean
(SD); median)
Male % Borderline ID % Mild
ID %
Moderate
ID %
Severe
ID %
Profound
ID %
Unspeciﬁed
ID %
Pawar and Akuffo
(2008) [33]
7 (1/3/3)
England, London
Borough of
Waltham Forest
Adults with ID in contact
with services. LS
residential homes,
supported living, private
homes
Adults in contact with one
CLDT (active cases)
17–65+ (ns; ns) 53.7 ns ns ns ns ns 100
Schieve et al. (2009)
[29]
4 (1/2/1)
US Children in households
with DS or with ID
without DS. DS 19.5%
National survey of
households
3–17 (ns; ns) 59.6a ns ns ns ns ns 100
Schieve et al. (2012)
[28]
3 (1/2/0)
US Children in households
with ID without autism
National survey of
households
3–17 (ns; ns) 58.1 ns ns ns ns ns 100
Steffenburg et al. (1995)
[41]
6 (2/3/1)
Sweden Children with ID in one
city born 1975–1986. CP
15.3%. LS ns
Education, inpatient,
outpatient, child
habilitation clinic and
child neuropsychiatric
clinic registers
6–13 (ns; ns) ns – 63.0 37.0   –
Strømme and Hagberg
(2000)
[48]
7 (2/4/1)
Norway Children with mild or
‘severe’ ID
(IQ<50 assumed mod/
sev/pro). Genetic cause
35%, CP 14%. LS ns
Multiple sources
(education and medical)
used to identify all in one
County
8–13 (ns; ns) 57.8 – 55.6 44.4   –
Temtamy et al. (1994)
[63]
4 (0/4/0)
Egypt Children with ID in
households. DS 2.6%, MCA
24.1%, primary CNS defect
12.9%
Households in three
localities in Egypt
2–18 (ns; ns) 68.1 30.8a 47.9a 21.4a   –
Tenenbaum et al.
(2012) [64]
1 (0/1/0)
Israel All with ID living in
residential centres. DS
8.1%, Fragile X 1.0%, Rett
syndrome 0.2%
Residential care centres 0–60+ (ns; ns) 56.3 – 13.3 41.1 31.6 13.4 0.6
van Schrojenstein
Lantman-de
Valk et al. (2000) [45]
4 (1/3/0)
Netherlands Any general practice
patients with ID. LS ns
Registration Network
Family Practices (RNH) of
Maastricht University
ns. 20% aged over
50, includes
children
62 ns ns ns ns ns 100
van Schrojenstein
Lantman-de
Valk et al. (1997) [44]
4 (0/1/3)
Netherlands People with ID in
institutions or group
homes. CP 11.8%,
dementia 3.8%, DS 22.3%
Institutions and group
homes
0–70+ (ns; ns) ns ns ns ns ns ns 100
Wellesley et al. (1992)
[59]
7 (2/3/2)
Australia Children in Western
Australia with ID born
1967–1976. CP 19.8%. LS
ns
Multiple services and
schools
6–16 (ns; ns) 59.6a – 38.5a 31.0a 12.6a 7.1a 10.7a
Wong (2011) [65]
5 (1/1/3)
Hong Kong Adults with ID in
residential care. DS 13.2%,
CP 16.7%
Residential care services 18–79 (44 (ns); ns) 53.3 – 4.9 41.8 51.9  –
Yousef (1995) [66]
6 (0/3/3)
Jordan Children at special schools
for ID. LS ns
Special education centres
in one City
ns; school age 73.8 – 27.2 44.2 28.6  –
Down syndrome studies
Collacott (1993)
[23]
7 (2/3/2)
England, Leicester-
shire
Adults with DS, dementia
5.1%. LS any
Leicestershire LD Register,
health service records, day
centres, residential
services
<30–60+ (ns; ns) ns ns ns ns ns ns 100
Johannsen et al.
(1996) [54]
7 (2/4/1)
Denmark DS in age groups 14–16,
23–29 and 50–60. LS ns
All in one County
identiﬁed via Danish
register and city councils
Age groups 14–16,
23–29, 50–60
62.5 ns ns ns ns ns 100
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McCarron et al.
(2005) [36]
4 (0/3/1)
Ireland Adults with DS aged 35+
in out-of-home
placements, AD 50.8%
Care settings (out-of-
home placements)
>35-ns (AD 55.4
(7.0); ns. Non-AD
50.8 (5.8); ns)
33.9 – – 69.4 30.6 – –
McVicker et al.
(1994) [50]
7 (2/3/2)
Northern Ireland Adults with DS living in
community (82%) or
hospital
Adults training centres,
social services register,
MH hospital
19–50+
(community 33.5
(ns); ns, hospital
54.5 (ns); ns)
ns ns ns ns ns ns 100
Prasher (1995)
[34]
4 (2/2/0)
England, West
Midlands
Adults with DS. LS
hospital, community or
family home
Cohort with DS in West
Midlands
16–72 (44.2 (12.5);
ns)
50.7 – 18.9 66.7 13.4 – 1.0
Pueschel et al. (1991)
[30]
4 (1/3/0)
US, Rhode Island Children and adults with
DS. LS family home, other
types ns
Child development centre
(enables near complete
ascertainment of DS)
0.5–45 (ns; ns) 52.1 ns ns ns ns ns 100
Roizen et al. (2014)
[31]
2 (1/1/0)
US, New York State Children with DS in New
York State. LS ns
Families registered in the
New York Congenital
Malformations Registry
(NYCMR)
3–14 (7.5 (3.1); ns) 51.7 ns ns ns ns ns 100
Tyrrell et al. (2001)
[37]
7 (2/4/1)
Ireland Adults with DS over age
35. Dementia 13.3%. LS
institutional, residential,
community
Learning disability
services
35–70+ (ns; ns) ns – ns ns ns ns 100
Authors, year and
quality scoreb
Method epilepsy ascertainment Epilepsy deﬁnition Epilepsy prevalence % inmain subgroup
conditions
Epilepsy
cases n
Sample
size N
Epilepsy
prevalence %
Airaksinen et al.
(2000) [42]
10 (2/4/4)
Parent questionnaire and interview,
medical records, examination, EEG
ILAE, epilepsy CP 62.5% 32 151 21.2
Arvio and Sillanpa¨a¨
(2003) [43]
4 (0/3/1)
ns assume medical records Epilepsy, ns DS, 30%
AE 83%
FXS 5.5%
239 461 51.8
Benassi et al.
(1990) [52]
3 (0/3/0)
Medical records and discussion with
school health service
Epilepsy, ns ns 27 90 30.0
Christianson et al.
(2002) [56]
3 (0/2/1)
Phase 1 TQQ screening, phase
2 paediatric evaluation
Epilepsy, ns ns 37 238 15.5
David et al. (2014) [53]
4 (0/3/1)
Carer telephone interview and medical
records
Epilepsy, ns ns 5 181 2.8
Dekker and Koot
(2003) [14]
2 (0/2/0)
Parent interview Epilepsy, ns ns 26a 474 5.5
Fernell (1998) [38]
3 (0/3/0)
Medical records, author personal
knowledge
Epilepsy, ns ns 17 64 26.6
Forsgren et al.
(1990) [39]
8 (2/2/4)
Asked staff in institutions and letters to
parents or carers, medical records
examined if reported epilepsy
Active1 SZ last 5 yrs
and/or on AED
FXS 23.5%
DS 5.9%
RS 80% (4/5)
299 1479 20.2
Gittins and Rose
(2008) [32]
5 (1/3/1)
Case notes Epilepsy in case notes ns 39 61 63.9
Goulden et al.
(1991) [49]
9 (2/3/4)
Parent interview and/or records
(medical, education, social work)
ILAE, epilepsy CP 37.5%, postnatal injury 73.3%,
Genetic or malformation e.g. DS 12.5%
33 215 15.3
Hand and Reid
(1996) [60]
1 (0/1/0)
Questionnaire completed by carer, staff
or GPs
Epilepsy, ns ns 177 1063 16.7
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Table 1 (Continued )
Authors, year and
quality scoreb
Method epilepsy ascertainment Epilepsy deﬁnition Epilepsy prevalence % inmain subgroup
conditions
Epilepsy
cases n
Sample
size N
Epilepsy
prevalence %
Haveman et al.
(2011) [55]
4 (1/2/1)
Carer interview Diagnosis epilepsy ns 351a 1253 28
Hove and Havik
(2010) [47]
1 (0/1/0)
Informant questionnaire
(personnel)
Epilepsy, ns ns 134a 593 22.6
Jelliffe-Pawlowski
et al. (2003) [25]
5 (1/3/1)
Service records Diagnosis epilepsy ns 160 603 26.5a
Koskentausta et al.
(2002) [15]
4 (0/3/1)
Case records Epilepsy, ns Psychiatrically non-disturbed 35%,
disturbed 37%
55 155 35.5
Lakhan (2013) [61]
7 (0/4/3)
Examination. EEG if
symptoms of epilepsy
Epilepsy, ns CP 46.3%, DS 10.5% 62 262 23.7
Lewis et al. (2000)
[58]
(2000)
3 (1/2/0)
Carer interview Seizures or epilepsy, lifetime ns. 115 392 29.3
Lin et al. (2003)
[62]
1 (0/1/0)
Parent or carer questionnaire Epilepsy, ns ns 262 1116 23.5a
Matthews et al.
(2008) [46]
3 (1/2/0)
Carer interview. If epilepsy, visit by
epilepsy nurse and information
assessed by 2 doctors (and
neuropsychiatrist if needed)
Diagnosis epilepsy ns 58 318 18.2
McBrien and Macken
(2009) [35]
3 (0/3/0)
Medical records (moderate), routine
medical review (severe or profound)
Epilepsy, ns ns 35 97 36.1
McCarron et al.
(2014) [10]
6 (1/2/3)
Questionnaire and interview
(carer)
Diagnosis epilepsy DS and dementia 52.2%, DS controlling
for dementia 13.4%
229 747 30.7
McDermott et al.
(2005) [26]
6 (2/3/1)
Medical records 1 AED DS 13.6%, CP 40% 186a 663 28.1
McGrother et al.
(2006) [22]
6 (1/2/3)
Carer interviews Suffers epilepsy (ns), seizures
occasionally, or on AED
ns 620 2393 25.9
Memisevic and
Sinanovic
(2009) [51]
7 (1/3/3)
Medical records Diagnosis epilepsy DS 0%,
other genetic cause 31.8%,
brain injury 48.6%
34 167 20.4
Molteno et al. (2001)
[57]
1 (0/1/0)
Teacher questionnaire Epilepsy, ns ns 84 355 23.7
Morgan et al. (2003)
[9]
7 (1/3/3)
Codes in multiple
databases
Epilepsy code in inpatient, MH hospital
or mortality datasets, or on epilepsy
clinic database
ns 257 1595 16.1
Murphy et al. (1995)
[27]
4 (0/3/1)
Records Epilepsy, ns ns 157 1074 14.6a
Nordin and Gillberg
(1996) [40]
6 (2/4/0)
Clinical interview
and medical examination
1 SZ or AED in last yr or SZs important
part of medical history
ns 22 101 21.8
J.
 R
o
b
ertso
n
 et
 a
l.
 /
 Seizu
re
 2
9
 (2
0
1
5
)
 4
6
–
6
2
5
2
Pawar and Akuffo
(2008) [33]
7 (1/3/3)
Case records Diagnosis epilepsy ns 53 177 29.9
Schieve et al.
(2009) [29]
4 (1/2/1)
Family carer interview SZ past 12 mths DS 1.4%, non-DS 16.3% (weighted
estimates)
98 750 13.1a
Schieve et al.
(2012) [28]
3 (1/2/0)
Carer interview SZ past 12 mths ns ns
36a
238 15.1 (weighted)
Steffenburg et al.
(1995) [41]
6 (2/3/1)
Medical ﬁles ILAE Active 2 unprovoked SZ and 1
SZ in last 5 yrs
CP 72.4%a 98 378 25.9
Strømme and
Hagberg (2000) [48]
7 (2/4/1)
Parent interview and examination ILAE, epilepsy ns 35 178 19.7
Temtamy et al.
(1994) [63]
4 (0/4/0)
Clinical examination Epilepsy, ns ns 5 116 4.3
Tenenbaum et al.
(2012) [64]
1 (0/1/0)
Residential centre report, assumed
records
Epilepsy, ns ns 2313 7067 32.7
van Schrojenstein
Lantman-de
Valk et al.
(2000) [45]
4 (1/3/0)
Electronic GP medical records Epilepsy code N88 ICPC ns 35 318 11.0
van Schrojenstein
Lantman-de
Valk et al.
(1997) [44]
4 (0/1/3)
GP questionnaire Epilepsy, ns DS 10.7%, non-DS 17.4%.
OR for epilepsy if dementia 8.8 (95% CI
4.8–16.2)
167a 1020 16.4
Wellesley et al.
(1992) [59]
7 (2/3/2)
Records. Clariﬁcation if needed via
examination or contacting doctor
(main source records)
2 major or minor convulsions in
absence of fever
ns 208 1590 13.1
Wong (2011) [65]
5 (1/1/3)
Nursing staff questionnaire Diagnosis epilepsy DS 13.2%, non-DS 37.0% 276 811 34.0
Yousef (1995) [66]
6 (0/3/3)
School records and teachers to clarify if
necessary
Epilepsy, ns ns 75 379 19.8
Down syndrome studies
Collacott
(1993) [23]
7 (2/3/2)
Carer interviews and medical records 3 SZ in 2 yrs, lifetime Dementia 27.8% 35 351 10.0
Johannsen et al.
(1996) [54]
7 (2/4/1)
Parent/carer interview and
examination
ILAE, epilepsy ns 12 72 16.7
McCarron et al.
(2005) [36]
4 (0/3/1)
Medical records Epilepsy, ns AD 55.5%, non-AD 11.4%,
end-stage AD 84.0%,
mid-stage AD 39.4%
42 124 33.9
McVicker et al.
(1994) [50]
7 (2/3/2)
Medical records 1 SZ in prior 2 yrs and/or on AED ns 18 191 9.4
Prasher
(1995) [34]
4 (2/2/0)
Carer interview 3 SZ in a 2 yr period and/or on AED
(excludes partial complex SZ)
Dementia in 34.4% of those with
epilepsy, total n with dementia not
identiﬁed
32 201 15.9
Pueschel et al.
(1991) [30]
4 (1/3/0)
Medical records and parent
questionnaire
SZ disorder, exclude single provoked or
unprovoked SZ
ns 33 405 8.1
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J. Robertson et al. / Seizure 29 (2015) 46–6254 Age
 Gender
 Level of intellectual disability
 Other – prevalence for other subgroup(s) given (e.g. those with
dementia)
A score was awarded if the information was presented in a
bar chart, or in an alternative format such as relative risk. Scores
could range from 0 to 4. Studies were not excluded based on
quality scores and scores are presented in the ﬁrst column of
Table 1.
2.4. Meta-analysis
For each study, the sample size and number of cases of epilepsy
in the sample were entered as effect size data in Comprehensive
Meta-Analysis Version 2.2 software (www.Meta-Analysis.com).
Prevalence estimates were pooled using random effects meta-
analysis. For the main random effects pooled estimates, heteroge-
neity between studies was summarised using I2 and Q statistics.
Subgroup analyses were conducted using between study modera-
tor variables and within study subgroups. To compare across
subgroups, the Q-test was used. Statistical signiﬁcance was set at p
value < .05.
3. Results
The process of identifying studies for inclusion is summarised in
Appendix B. Electronic database searches identiﬁed a total of
1332 references, with 1099 remaining after removal of duplicates.
Following the ﬁrst examination of studies, 144 remained in a pool
of articles relating to prevalence or mortality. After examination of
full text articles from this pool and the addition of articles cited
within these, 48 articles met the criteria for inclusion in relation to
the prevalence of epilepsy and these are summarised in
Table 1. Studies only including people with Down syndrome are
presented separately at the end of Table 1.
3.1. Geographical spread
The majority of studies (42) were from high income countries,
with just six studies from Low and Middle Income countries. The
studies included a wide range of countries, with the greatest
number for one country being seven studies from the United States
[25–31].
A large number were from European countries: ﬁve were from
England [22,23,32–34]; four from Ireland [10,35–37]; four from
Sweden [38–41]; three from Finland [15,42,43]; three from the
Netherlands [14,44,45]; two from Wales [9,46]; two from Norway
[47,48]; one study each from Scotland [49], Northern Ireland [50],
Bosnia and Herzegovina [51], Italy [52], France [53], and Denmark
[54]; and one study included 14 European countries [55].
In addition, there were two studies from South Africa [56,57]
and two from Australia [58,59]. Finally, one study each was
included from the following countries: New Zealand [60]; India
[61]; Taiwan [62]; Egypt [63]; Israel [64]; Hong Kong [65]; and
Jordan [66].
3.2. Study design
Studies were almost entirely cross-sectional and based on
retrospective review of records, questions completed either by
self-report or interview, or clinical examination. There were three
prospective cohort studies [42,44,49] although in the latter authors
only present prevalence rates for the last data collection round. In
J. Robertson et al. / Seizure 29 (2015) 46–62 55one retrospective study people could be included in more than one
age-band estimate as there was an average of 12 years of follow-up
for those with disabilities [26].
3.3. Meta-analysis
Two studies were excluded from meta-analyses as they focused
on seizures in the last 12 months rather than epilepsy per se
[28,29]. For prospective or retrospective cohort studies where
people could be included in prevalence estimates at more than one
time point, only the most recent data collection point was
included. Analyses looked at subgroups using between study
moderator variables, and also within study subgroups.
3.3.1. General samples versus samples of people with Down syndrome
An a priori decision was taken to compare studies based solely
on samples of people with Down syndrome to general samples of
people with intellectual disabilities. This was done in view of
evidence suggesting that the prevalence of epilepsy is lower in
people with Down syndrome than in general samples of people
with intellectual disabilities (although these general sample
ﬁgures are likely to include a number of people with Down
syndrome). Whether or not studies included only people with
Down syndrome was used as a between study moderator variable
(see Table 2). The pooled estimate for 38 studies of general samples
of people with intellectual disabilities was 22.2% (95% CI 19.6–
25.1). There was signiﬁcant heterogeneity between the studies
(I2 = 96.4%, Q = 1025.2, df = 37, p < .001). The pooled estimate for
studies including only people with Down syndrome was 13.6%
(95% CI 9.9–18.4). There was signiﬁcant heterogeneity betweenTable 2
Random effects meta-analysis pooled estimates of prevalence of epilepsy.
Subgroup Number of studies Prevalence %a
Down syndrome 
Mixed sample 38 22.2 
Down syndrome only 8 13.6 
Level of IDb
All 29 22.2 
Less severe 4 7.3 
More severe 5 41.6 
Ageb,c
Adult 12 23.5 
Child 12 21.7 
Mixed 5 20.2 
High/LAMIb,c
High 25 22.4 
LAMI 4 20.5 
Subgroup (including within study subgroups)
Level of ID 
Mild 13 9.8 
Moderate/severe/profound 14 30.4 
Level of ID (where moderate, severe, profound available separately) 
Moderate 5 16.7 
Severe 3 27.0 
Profound 4 50.9 
Gender (any study where male/female ﬁgures given separately) 
Male 9 24.8 
Female 9 22.2 
Age groupsb,c
0–18 11 21.6 
19–49 8 26.0 
50+ 7 21.5 
a Estimates based on meta-analysis using random effects model.
b Excludes DS only studies.
c Excludes less/more severe ID studies.studies (I2 = 91.7%, Q = 84.3, df = 7, p < .001). Fig. 1 presents a forest
plot of the 38 studies based on general samples and the 8 studies
based on samples of people with Down syndrome only.
3.3.2. Level of intellectual disability
For studies using general samples of people with intellectual
disabilities, level of intellectual disability was used as a between
study moderator variable (see Table 2). This classiﬁed studies as:
‘All’ (study representative of all levels of intellectual disability);
‘Less’ (study representative of those with less severe intellectual
disabilities e.g. excludes those with severe/profound intellectual
disability); ‘More’ (study representative of those with more
severe intellectual disabilities e.g. excludes those with mild
intellectual disability). The pooled estimate for studies including
all levels of intellectual disability was 22.2% (95% CI 19.6–25.0),
whereas the estimate for studies classed as ‘less severe’ was 7.3%
(95% CI 4.5–11.6) and the estimate for ‘more severe’ 41.6% (95% CI
32.1–51.8). In view of the effect of level of intellectual disability
on pooled prevalence estimates, subsequent analyses only
included those 29 studies which included all levels of intellectual
disability.
3.3.3. Age group
Broad age group was used as a between study moderator
variable for the 29 studies which included all levels of intellectual
disability and which were not restricted to people with Down
syndrome. Age group was classed as adult, child, or mixed (adult
and child). This was based on the main age group of the study
sample, so for example a study would be classed as ‘adult’ if it
included mainly adults and a small number of 16 year olds, and a95% CI lower 95% CI upper
Q 8.7, df 1, p .003
19.6 25.1
9.9 18.4
Q 43.4, df 2, p < .001
19.6 25.0
4.5 11.6
32.1 51.8
Q 0.8, df 2, p .661
19.5 28.0
17.9 26.1
15.0 26.7
Q 0.2, df 1, p .626
19.7 25.4
14.5 28.2
Q 56.0, df 1, p < .001
7.6 12.4
25.5 35.7
Q 16.6, df 2, p < .001
10.8 25.0
16.1 41.5
36.1 65.5
Q 0.4, df 1, p .524
19.6 30.8
17.3 28.1
Q 2.2, df 2, p .339
17.9 25.9
21.2 31.5
17.0 26.9
Group  by
DS
Study na me Statistics  for each study Event  rate and  95 % CI
Event Lo wer  Upp er 
rate li mit li mit Z-Value p-Value
No Airaksinen , Matilainen , Mon one n et  al (2000 ) 0.212 0.154 0.284 -6.59 6 0.00 0
924.0297.0465.0374.0815.0)3002(ääpnalliS&oivrAoN
No Bena ssi, Gua rino,  Camm arata et al (199 0)  0.300 0.214 0.402 -3.68 4 0.00 0
No Christianson, Zwan e,  Mang a et  al (2002 ) 0.155 0.115 0.207 -9.46 0 0.00 0
No David, Dieterich, de  Villemeur et  al (2014 ) 0.028 0.012 0.065 -7.85 2 0.00 0
000.0211.41-970.0830.0550.0)3002(tooK&rekkeDoN
000.0395.3-683.0271.0662.0)8991(llenreFoN
No Forsgren , Edvinsson, Blomquist  et  al (1990 ) 0.202 0.182 0.223 -21 .204 0.00 0
230.0741.2947.0215.0936.0)8002(esoR&snittiGoN
No Goulden,  Shinn ar,  Koll er et  al (1991 ) 0.153 0.111 0.208 -9.02 5 0.00 0
000.0265.91-091.0541.0761.0)6991(dnaHoN
No Haveman , Perry, Salvador-Carulla et al (201 1) 0.280 0.256 0.306 -15 .003 0.00 0
000.0935.21-162.0491.0622.0)0102(kivaH&evoHoN
No Jelliffe-Pawlowski,  Shaw, Ne lson et al (2003) 0.265 0.232 0.302 -11 .041 0.00 0
No Kosk entau sta, Iivanainen & Almqvist (2002 ) 0.355 0.284 0.433 -3.56 1 0.00 0
000.0750.8-292.0981.0732.0)3102(nahkaLoN
No Lewis, Tonge , Mowat et  al (200 0) 0.293 0.250 0.340 -7.92 5 0.00 0
000.0137.61-162.0112.0532.0)3002(eeL&uW,niLoN
No Matt hews, Weston , Baxter et al (2008 )  0.182 0.144 0.229 -10 .331 0.00 0
No McBrien & Macken  (20 09) 0.361 0.272 0.461 -2.70 4 0.00 7
No McCarron, O'Dwyer,  Burke et al (2014 ) 0.307 0.275 0.341 -10 .286 0.00 0
No McDermott, Moran , Platt  et al  (20 05) 0.281 0.248 0.316 -10 .894 0.00 0
No McGrothe r, Bhau mik,  Tho rp et  al (2006 ) 0.259 0.242 0.277 -22 .520 0.00 0
No Memisevic & Sinan ovic (2009) 0.204 0.149 0.271 -7.09 8 0.00 0
No Molteno, Molteno,  Finchilescu et al (200 1) 0.237 0.195 0.284 -9.37 9 0.00 0
No Morga n,  Baxter & Kerr (2003) 0.161 0.144 0.180 -24 .225 0.00 0
No Murph y,  Yeargin -Allsop p,  Decouflé et al (199 5) 0.146 0.126 0.169 -20 .434 0.00 0
000.0303.5-903.0841.0812.0)6991(greblliG&nidroNoN
000.0971.5-173.0732.0992.0)8002(offukO&rawaPoN
No Steffenburg,  Hagbe rg, Vigg eda l et al  (19 95) 0.259 0.218 0.306 -8.94 5 0.00 0
No Strømme & Hagbe rg (2000 ) 0.197 0.145 0.262 -7.46 3 0.00 0
No Temtamy, Kan dil,  Demerdash et  al (199 4) 0.043 0.018 0.099 -6.78 1 0.00 0
No Tenen baum,  Fuchs, Raskas et  al (2012 ) 0.327 0.316 0.338 -28 .418 0.00 0
No van  Schrojenstein Lan tman-de Valk et  al (20 00) 0.110 0.080 0.149 -11 .665 0.00 0
No van  Schrojenstein Lan tman-de Valk et  al (19 97) 0.164 0.142 0.188 -19 .272 0.00 0
No Well esley, Hockey, Montgo mery et al (1992) 0.131 0.115 0.148 -25 .463 0.00 0
000.0139.8-473.0903.0043.0)1102(gnoWoN
000.0558.01-142.0161.0891.0)5991(fesuoYoN
000.0372.51-152.0691.0222.0oN
000.0253.21-631.0270.0001.0)3991(ttocalloCseY
Yes Johan nsen , Christensen, Goldstein et al (199 6) 0.167 0.097 0.271 -5.08 9 0.00 0
Yes McCarron, Gill, McCallion et al (200 5) 0.339 0.261 0.426 -3.52 6 0.00 0
Yes McVicker, Sha nks & McClellan d (19 94) 0.094 0.060 0.145 -9.13 7 0.00 0
000.0236.8-612.0511.0951.0)5991(rehsarPseY
Yes Pueschel, Louis & McKnigh t (199 1) 0.081 0.059 0.112 -13 .337 0.00 0
Yes Roizen, Magyar, Kusc hner et  al (20 14) 0.068 0.048 0.096 -13 .826 0.00 0
Yes Tyrrell, Cosgrave,  McCarr on et  al (2001 ) 0.205 0.162 0.256 -9.20 6 0.00 0
000.0130.01-481.0990.0631.0seY
000.0341.5-082.0801.0871.0llarevO
-1.00 -0.50 0.00 0.50 1.00
Fig. 1. Forest plot of prevalence for mixed samples versus Down syndrome only.
J. Robertson et al. / Seizure 29 (2015) 46–6256study would be classed as ‘child’ if it included mainly children and
a small number of 20 year olds. Estimates for these broad age
groups did not differ signiﬁcantly (see Table 2).
3.3.4. Country economy
Country economy (High or Low and Middle Income (LAMI))
was also used as a between study moderator variable for the
29 studies which included all levels of intellectual disability and
which were not restricted to people with Down syndrome.
Countries in which studies were undertaken were classed as ‘high
income’ or ‘low and middle income’ based on the World Bank list
of economies [67]. This classiﬁes countries according to 2013 gross
national income (GNI) per capita: low income, $1045 or less;
lower middle income, $1046–4125; upper middle income, $4126–
12,745; and high income, $12,746 or more. Taiwan (not included
in country classiﬁcation) was classed as High Income. One study
included 14 European countries of which one was upper middle
income and this study overall was classed as ‘high income’
[55]. There was no signiﬁcant difference in the pooled estimates
(see Table 2).3.4. Within study subgroup analyses
Further meta-analyses were then conducted which included
information on prevalence from within study subgroups, for
example where studies presented prevalence rates separately by
level of intellectual disability, gender or age bands. Studies which
only included a relevant subgroup (e.g. a sample including only
people with mild intellectual disability) were also included in
these analyses.
3.4.1. Level of intellectual disability
For level of intellectual disability, ﬁrstly prevalence rates were
included for those with mild intellectual disability and the
combined prevalence for those with moderate, severe or profound
intellectual disability. Combining moderate, severe and profound
intellectual disability was done to maximise the number of studies
that could be included as few studies presented results for each
of these three levels of intellectual disability separately. The
pooled estimate for moderate/severe/profound intellectual dis-
ability from 14 studies was 30.4% (95% CI 25.5–35.7) compared to
J. Robertson et al. / Seizure 29 (2015) 46–62 579.8% (95% CI 7.6–12.4) from 13 studies for those with mild
intellectual disability (see Fig. 2).
Pooled estimates were also calculated for the studies which did
provide separate estimates for any of the moderate, severe or
profound categories. For moderate intellectual disability, the
pooled estimate was 16.7% (95% CI 10.8–25.0), compared to
27.0% (95% CI 16.1–41.5) for severe intellectual disability and
50.9% (95% CI 36.1–65.5) for profound intellectual disability.
3.4.2. Gender
Where male and female prevalence ﬁgures were given
separately, pooled estimates were male 24.8% (95% CI 19.6–
30.8) and female 22.2% (17.3–28.1). One study in the male/female
subgroup analysis only included those with mild or moderate
intellectual disability but was nonetheless included in the analysis
[51].
3.4.3. Age group
Studies presenting results separately for age bands were
considered using age band as a subgroup within study. Studies
presenting results for only one age band were also included in this
analysis. The broad age bands used were 0–18, 19–49, and 50+.
However, a 5 year leeway was given for these age bands at both the
upper and lower limit so, for example, a ﬁgure for those aged 19–54
or 17–54 would be included in the 19–49 category. Age bands from
McDermott et al. [26] were not included as due to participants
having an average of 12 years of follow-up time a person could be
in more than one age band and they were thus not independent
subgroups. Figures for a speciﬁc age (e.g. age 22) were included in
the appropriate age band. Overall, there was not a signiﬁcant
difference by age band although the prevalence for age band 19–49
(26.0% (95% CI 21.2–31.5)) was slightly higher than that for the 0–
18 age band (21.6% (95% CI 17.9–25.9) and the 50+ age group
(21.5% (95% CI 17.0–26.9).
3.5. Down syndrome
Eight studies focussed exclusively on people with Down
syndrome [23,30,31,34,36,37,50,54]. A further eight studies
included some results disaggregated for people with Down
syndrome in the overall sample. Results from meta-analyses
in relation to people with Down syndrome are given in Table 3. InGroup by
Subgroup within study
Stud y na me Subg roup  within study Statistics fo
Eve nt  Lower  Upp 
rate limit lim
1.0820.0860.0dliM)0002( la te nenonoM ,nenialitaM ,neniskariAdliM
1.0290.0331.0dliM)2002( la te agnaM ,enawZ ,nosnaitsirhCdliM
0.0210.0820.0dliM)4102( la te ruemelliV ed ,hcireteiD ,divaDdliM
1.0480.0211.0dliM)0991( la te tsiuqmolB ,nossnivdE ,nergsroFdliM
1.0360.0101.0dliM)1991( la te relloK ,rannihS ,nedluoGdliM
1.0201.0531.0dliM)3002( la te nosleN ,wahS ,ikswolwaP-effilleJdliM
1.0210.0830.0dliM)3102( nahkaLdliM
2.0001.0561.0dliM)9002( civonaniS & civesimeMdliM
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1.0330.0860.0dliM)5991( fesuoYdliM
Mild 0.09 8 0.07 6 0.1
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Fig. 2. Forest plot for prevalence mild versus modthese analyses, prevalence rates from studies looking only at
people with Down syndrome were combined with prevalence
rates given in other studies which presented results for people
with Down syndrome as a within study subgroup (excluding
studies which did not include all levels of intellectual disability).
No rates disaggregated by gender were identiﬁed.
Firstly, pooled prevalence for people with Down syndrome was
estimated by combining the prevalence rates from studies looking
only at people with Down syndrome with prevalence rates for
people with Down syndrome presented as a within study subgroup
(excluding studies which did not include all levels of intellectual
disability). The pooled estimate was 12.4% (95% CI 9.1–16.7). There
was signiﬁcant heterogeneity between studies, I2 = 87.4%, Q = 95.3,
df = 12, p < .001.
Pooled prevalence was also estimated for age bands. This
showed a signiﬁcant effect of age band, with the pooled estimate
rising from 6.9% (95% CI 3.8–12.0) at age 0–18, to 9.0% (95% CI 5.9–
13.5) at age 19–49, and 26.0% (95% CI 16.1–39.2) at age 50+.
In view of the increased rate of epilepsy in older people with
Down syndrome, overall prevalence was then estimated excluding
two studies which looked at samples of people with Down
syndrome aged 35+ only [36,37]. Based on data from 11 studies,
the pooled estimate was 10.3% (95% CI 8.4–12.6), I2 = 57.0%,
Q = 23.2, df = 10, p < .01. However, it should be noted that these
studies did not include all age bands, with some including only
adults and other including only children.
Finally, a small number of studies presented prevalence rates
separately for those with and without Alzheimer’s disease/
dementia. The pooled prevalence for those with Alzheimer’s/
dementia was 53.3% (95% CI 41.9–64.4) compared to 12.8% (95% CI
7.7–20.4) for those speciﬁcally noted not to have Alzheimer’s/
dementia. It is not possible to give the mean age for those with and
without Alzheimer’s disease/dementia overall. However, the mean
age for both groups is available in two studies: 54.7 (SD 7.5) for
those with Alzheimer’s disease/dementia compared to 45.6 (SD
7.3) for those without [37]; and 55.4 (SD 7.0) for those with and
50.8 (SD 5.8) for those without [36] (see Fig. 3).
3.6. Co-morbidity
A number of studies presented data on co-morbidities in people
with intellectual disabilities and epilepsy.r each study Event  rate and  95 % CI
er 
it Z-Value p-Value
000.0766.5-25
000.0588.8-98
000.0258.7-56
000.0566.21-84
000.0665.8-65
000.0513.11-77
000.0194.5-11
000.0255.5-95
000.0390.81-19
000.0506.9-89
000.0685.6-66
000.0691.61-14
000.0886.6-63
2 4 -15.943 0.000
010.0085.2-36
000.0486.3-20
200.0550.3-50
000.0395.3-68
000.0827.61-95
240.0130.2-59
300.0500.3-96
000.0604.4-40
700.0407.2-16
000.0352.6-57
832.0181.1-33
300.0479.2-04
000.0026.71-87
000.0469.7-20
5 7 -6.706 0.000
6 1 -2.186 0.029
-1.00 -0.50 0.00 0.50 1.00
erate/severe/profound intellectual disability.
Table 3
Meta-analysis estimates for people with Down syndrome.
Subgroup Number
of studies
Prevalence %a 95% CI lower 95% CI upper
Overall prevalence including subgroups
in non-DS only studiesb
13 12.4 9.1 16.7
Overall prevalence including subgroups
in non-DS only studiesb excluding
two studies on older people
11 10.3 8.4 12.6
Ageb Q 15.0, df 2, p .001
0–18 2 6.9 3.8 12.0
19–49 3 9.0 5.9 13.5
50+ 3 26.0 16.1 39.2
Has Alzheimer’s/dementia Q 30.9, df 1, p < .001
Yes 4 53.3 41.9 64.4
No 2 12.8 7.7 20.4
a Estimates based on meta-analysis using random effects model.
b Excludes less/more severe ID studies.
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One study reported that epilepsy was associated with higher
levels of psychopathology [57] and one study (controlling for age,
gender and level of understanding) found associations with
epilepsy and some psychological and behaviour problems
[22]. However, other studies found that people with intellectual
disability and epilepsy were not more likely to have co-morbid
psychiatric and/or behavioural problems than those with intellec-
tual disabilities without epilepsy. Reported ﬁndings include: being
signiﬁcantly less likely to have behavioural disturbances (17.6% vs
27.9%) [43]; no signiﬁcant difference in the prevalence of
psychiatric disorders [15]; no signiﬁcant differences in behavioural
and emotional disturbance when controlling for level of intellec-
tual disability [58]; no signiﬁcant differences in psychopathology
between matched epilepsy and non-epilepsy groups [46]; no
association between epilepsy and mental health concerns, with
46.7% of those with epilepsy reporting mental health problems
compared with 48.1% of those without epilepsy [10]; no
association between epilepsy and the prevalence of challenging
behaviour or psychiatric conditions [33]; and no signiﬁcant
difference in maladaptive behaviour scores for those with Down
syndrome and epilepsy [34].
3.6.2. Physical impairments
People with intellectual disabilities and epilepsy were found to
have more associated impairments (2.7) than those without
epilepsy (1.2) and were more likely to have: speech handicap
(73.6% versus 50.0%), motor handicap (54.4% versus 14.4%), and
blindness (14.2% versus 1.4%) [43]. Other reported co-morbidities
in those with epilepsy were: cerebral palsy (33.4%) and visual
impairment (12.4%) [39]; cerebral palsy (36.4%) [49]; and cerebralGrou p by
Subg rou p within study
Study name Subgroup  within study Statistics  for ea
Eve nt  Lower  Upper 
rate li mit li mit 
915.0121.0872.0aitnemeD/DA)3991(ttocalloCaitnemeD/DA
376.0234.0655.0aitnemeD/DA)5002(latenoillaCcM,lliG,norraCcMaitnemeD/DA
097.0694.0856.0aitnemeD/DA)1002(latenorraCcM,evargsoC,llerryTaitnemeD/DA
217.0523.0225.0aitnemeD/DA)4102(lateekruB,reywD'O,norraCcMaitnemeD/DA
AD/Dementia 0.533 0.419 0.64 4
Non AD/Demen tia McCarr on,  Gill, McCalli on et al (2005) Non AD/Dementia 0.115 0.056 0.22 2
Non AD/Demen tia Tyrrell, Cosgrave,  McCarron et al (2001 ) Non AD/Dementia 0.135 0.097 0.18 3
Non AD/Demen tia 0.128 0.077 0.20 4
Overall 0.292 0.052 0.75 5
Fig. 3. Forest plot for prevalence by Alzheimer’s/palsy (43%) and visual impairment (24.5%) [41]. After adjusting for
age, gender and level of understanding, those with epilepsy were
more likely to have: a range of physical disabilities (adjusted OR
1.8, 95% CI 1.5–2.2); problems with wetting (OR 2.7, 95% CI 2.1–
3.4), soiling (OR 2.2, 95% CI 1.6–3.1) and walking (OR 2.5, 95% CI
2.0–3.2) [22]. Those with intellectual disability were also found to
be more likely to have joint disease (29.3% versus 16.8% for those
with intellectual disability without epilepsy, adjusted OR 2.1, 95%
CI 1.5–3.1), gastrointestinal disease (34.5% versus 23.4%, adjusted
OR 1.8, 95% CI 1.3–2.5), and stroke (5.2% versus 1.9%, adjusted OR
3.3, 95% CI 1.4–9.0) [10].
4. Discussion
Despite the variation in reported prevalence rates between
studies, it is clear that the prevalence of epilepsy is high in
people with intellectual disabilities worldwide. The results
suggest that in general samples of people with intellectual
disabilities, approximately one in ﬁve people will have epilepsy,
with the pooled estimate from 38 studies being 22.2% (95% CI
19.6–25.1). For samples of people with Down syndrome
excluding two studies focusing on older people, the rate is
lower with approximately one in ten people having epilepsy,
with the pooled estimate from data in 11 studies being 10.3%
(95% CI 8.4–12.6). In studies where this information was
available, those with intellectual disabilities and epilepsy had
more physical impairments than those without epilepsy.
However, whilst psychiatric or behavioural co-morbidity was
common, rates were not necessarily higher than in those with
intellectual disabilities without epilepsy. A review speciﬁcally
addressing co-morbidity in people with intellectual disabilitiesch stud y Event rate and 95% CI
Z-Value p-Value
960.0618.1-
973.0088.0
650.0219.1
538.0802.0
 0.56 5 0.57 2
 -5.086 0.00 0
 -9.940 0.00 0
 -6.735 0.00 0
 -0.865 0.38 7
-1.00 -0.50 0.00 0.50 1.00
dementia for people with Down syndrome.
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prevalence (e.g. [68]) would be a useful addition to the
literature.
The prevalence of epilepsy is related to level of intellectual
disability. In 29 studies which included all levels of intellectual
disability, the pooled estimate was 22.2% (95% CI 19.6–25.0),
whilst for four studies with samples skewed towards less severe
intellectual disability the pooled estimate was 7.3% (95% CI 4.5–
11.6) and for ﬁve studies skewed towards more severe intellectual
disability the pooled estimate was 41.6% (95% CI 32.1–51.8).
Similarly, data from 13 studies gives a pooled estimate for those
with mild intellectual disability of 9.8% (95% CI 7.6–12.5)
compared to 30.4% (95% CI 25.5–35.7) for those with moderate,
severe or profound intellectual disability. Few studies give ﬁgures
separately for those with moderate, severe or profound intellectual
disability but it is clear that prevalence increases with level of
intellectual disability. The pooled estimate for moderate intellec-
tual disability from ﬁve studies was 16.7% (95% CI 10.8–25.0),
for severe intellectual disability from three studies 27.0% (95% CI
16.1–41.5) and for profound intellectual disability from four
studies 50.9% (95% CI 36.1–65.5).
Age was not found to be a signiﬁcant factor for general samples
of people with intellectual disabilities, although the rate for those
aged 19–49 was slightly higher at 26.0% (95% CI 21.2–31.5) than
for 0–18 year olds (21.6%, 95% CI 17.9–25.9) and 50+ year olds
(21.5%, 95% CI 17.0–26.9). However, for people with Down
syndrome there was a clear increase in prevalence with age. Data
from two studies for those aged 0–18 gave a pooled estimate of
6.9% (95% CI 3.8–12.0), compared to 9.0% (95% CI 5.9–13.5) for
three studies giving data for 19–49 year olds and 26.0% (95% CI
16.1–39.2) for three studies giving data for those aged 50 or more.
An increase with age was also found for people with Down
syndrome in a study by van Schrojenstein Lantman-de Valk et al.
[44], with the rates being 4.9% at age 0–19, rising to 36.4% for those
age 60 or more. However, it was not possible to include these
ﬁgures in the meta-analysis as sample sizes for individual age
bands were not identiﬁed. Similarly, an increasing prevalence of
epilepsy with age was found for a small sample of people with
Down syndrome [26] but these ﬁgures could not be included in the
meta-analysis due to participants being included in more than one
age band estimate depending on the number of years the person
was followed up for.
Overall, it is clear that for people with Down syndrome, epilepsy
prevalence increases with age. This increase is likely to be mainly
accounted for by the increasing presence of Alzheimer’s disease/
dementia in people with Down syndrome as they age. The pooled
estimate for those with Alzheimer’s disease/dementia from four
studies was 53.3% (95% CI 41.9–64.4) compared to 12.8% (95% CI
7.7–20.4) for two studies explicitly giving data for those without
Alzheimer’s/dementia. Further, in one study, epilepsy was found
here to be signiﬁcantly more common in persons at end-stage
(84.0%) versus persons at mid-stage Alzheimer’s disease (39.4%)
[36].
4.1. Limitations
There are a number of limitations to this review. Whilst
studies were identiﬁed from a large range of countries, the
review is restricted to English language publications. All data
was extracted by one reviewer and extraction of data by two
reviewers independently would have reduced the possibility of
errors. In some instances it was necessary to calculate ﬁgures
from reported data as they were not reported explicitly (e.g.
obtaining the number of epilepsy cases from the overall sample
number and reported prevalence rate or vice versa) and two
minor discrepancies arose. Firstly, calculating ﬁgures fromMcVicker et al. [50] on prevalence by age band resulted in a
total number of epilepsy cases of 19 compared to a reported
number of 18. Secondly, calculating ﬁgures from Wong [65] on
prevalence in a subgroup with Down syndrome resulted in a
prevalence rate of 13.1% compared to a rate of 13.2% as reported
in the article.
Ideally, the same deﬁnition of epilepsy should be used across
studies to allow comparison of prevalence rates [4]. However,
many of the studies identiﬁed did not present a deﬁnition of
epilepsy, generally referring to either a diagnosis of epilepsy or
the presence of epilepsy. The lack of detail given regarding the
deﬁnition of epilepsy in many studies means that it is not possible
to determine whether reported prevalence rates related to active
epilepsy or lifetime epilepsy. The issue of deﬁning epilepsy is not
straightforward [69]. Where deﬁnitions were provided, these
included standard deﬁnitions based on International League
Against Epilepsy (ILAE) criteria and other deﬁnitions specifying
variable criteria in relation to number of seizures, anti-epileptic
drug (AED) use and time spans. In addition, the source of
information used to ascertain epilepsy is variable between
studies which may lead to varying levels of accuracy in obtained
rates.
In addition to the variation in prevalence rates that is likely to
be due to differences in the deﬁnition of epilepsy used and the
source of data in studies, there is also likely to be an unknown
number of cases where epilepsy has been misdiagnosed due to the
misinterpretation of behavioural, physiological, syndrome related,
medication related or psychological events by parents, paid carers
and health professionals [70].
Finally, the review has focussed on prevalence in the general
population of people with intellectual disabilities or Down
syndrome and has not included studies on less common
syndromes such as Fragile X syndrome. Future review work could
consider prevalence in a greater range of speciﬁc syndromes
associated with intellectual disabilities.
5. Conclusion
This review aims to provide an up to date summary of research
on the prevalence of epilepsy in people with intellectual
disabilities. The pooling of estimates from studies, and the
examination of factors which account for some of the heterogene-
ity of reported prevalence rates between studies, allows for the
provision of more robust ﬁgures on prevalence. With around one in
ﬁve people with intellectual disabilities having epilepsy, it is
important that services are equipped with the information and
skills needed to manage epilepsy in this population. A recent report
provides information on reasonable adjustments that can be made
to improve epilepsy care for people with intellectual disabilities
[71] The ideas, information and examples of good practice in
relation to reasonable adjustments provided within this report
should help services improve provision for this highly prevalent
condition.
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MEDLINE AND CINAHL
Limits: 1990; English; Human
(TI (learning N1 (disab* or difﬁcult* or handicap*)) OR TI (mental* N1 (retard* or disab*
or deﬁcien* or handicap* or disorder*)) OR TI (intellectual* N1 (disab* or impair* or
handicap*)) OR TI development* N1 disab* OR TI (multipl* N1 (handicap* or disab*))
OR TI ‘‘Down* syndrome’’ OR (MH ‘‘Developmental Disabilities/EP/MO’’) OR (MH
‘‘Intellectual Disability+/EP/MO’’) OR (MH ‘‘mentally disabled persons’’)) OR (AB
(learning N1 (disab* or difﬁcult* or handicap*)) OR AB (mental* N1 (retard* or disab*
or deﬁcien* or handicap* or disorder*)) OR AB (intellectual* N1 (disab* or impair* or
handicap*)) OR AB development* N1 disab* OR AB (multipl* N1 (handicap* or
disab*)) OR AB‘‘Down* syndrome’’)
AND
(MH ‘‘Epilepsy+/MO/EP’’) OR (TI epilep* OR TI seizure* OR TI convulsi* OR AB epilep*
OR AB seizure* OR AB convulsi*)
AND
(TI incidence OR TI prevalence OR TI mortality OR TI death OR AB incidence OR AB
prevalence OR AB mortality OR AB death) OR (MH ‘‘Incidence’’) OR (MH
‘‘Prevalence’’) OR (MH ‘‘Mortality+’’)Appendix B. Flowchart of study identiﬁcation
Records  identified  through  da tabase 
searc hing
(n =  1332 )
Records  after du plicate s rem oved
(n =  1099 )
Selecte d based on  abstr act 
and title (n =1 44)  screened
Exc luded b ased o n abstract  and t itle (n=955)
Arti cles assessed as  eligible 
for inclus ion
(n = 32 )
Art 
Stud ies included  in ta bulation
(n = 48  )
Stud ies included  in meta -
analysis
(n =  46 )
Dup licates (n = 233)
Exc luded fo llowing consider ation of f ull 
text (n = 112)PSYCINFO
Limits: 1990, Peer review, English, Exclude dissertations
DE ‘‘Epilepsy’’ OR DE ‘‘Epileptic Seizures’’ OR (DE ‘‘Seizures’’ OR DE ‘‘Audiogenic
Seizures’’ OR DE ‘‘Epileptic Seizures’’ OR DE ‘‘Grand Mal Seizures’’ OR DE ‘‘Petit
Mal Seizures’’ OR DE ‘‘Status Epilepticus’’) OR (TI epilep* OR TI seizure* OR TI
convulsi* OR AB epilep* OR AB seizure* OR AB convulsi*)
AND
(TI incidence OR TI prevalence OR TI mortality OR TI death OR AB incidence OR AB
prevalence OR AB mortality OR AB death) OR DE ‘‘Epidemiology’’ OR DE ‘‘death
and dying’’ OR DE ‘‘mortality rate’’
AND
DE ‘‘Intellectual Development Disorder’’ OR DE ‘‘mental retardation’’ OR DE
‘‘developmental disabilities’’ OR (TI (learning N1 (disab* or difﬁcult* or
handicap*)) OR TI (mental* N1 (retard* or disab* or deﬁcien* or handicap* or
disorder*)) OR TI (intellectual* N1 (disab* or impair* or handicap*)) OR TI
development* N1 disab* OR TI (multipl* N1 (handicap* or disab*)) OR TI ‘‘Down*
syndrome’’) OR AB (mental* N1 (retard* or disab* or deﬁcien* or handicap* or
disorder*)) OR AB (intellectual* N1 (disab* or impair* or handicap*)) OR AB
development* N1 disab* OR AB (multipl* N1 (handicap* or disab*)) OR AB ‘‘Down*
syndrome’’icles ident ified fro m citat ions
(n = 16  )
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